A new way to deliver medicine for bladder cancer
An urinary drug disposing approach for treatment of bladder Cancer
['FUNDING_R01'] · WEILL MEDICAL COLL OF CORNELL UNIV · NIH-11126590
This project is creating a new way to deliver bladder cancer medicine through the bloodstream, aiming to improve treatment for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WEILL MEDICAL COLL OF CORNELL UNIV (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11126590 on ClinicalTrials.gov |
What this research studies
Many people with bladder cancer are diagnosed early, but the cancer often comes back even after surgery and current treatments. Existing treatments are given directly into the bladder, which can be uncomfortable, may not reach all tumors, and sometimes faces drug shortages. This project is developing a special peptide that can carry medicine to the urinary system when given through an IV, rather than directly into the bladder. This could make treatment more effective and easier for patients.
Who could benefit from this research
Good fit: This research is relevant for patients with non-muscle invasive bladder cancer and potentially those with muscle-invasive bladder cancer who cannot undergo surgery.
Not a fit: Patients whose cancer is not related to the urinary system or who do not have bladder cancer would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this new drug delivery method could lead to more effective bladder cancer treatments, potentially reducing recurrence rates and improving survival.
How similar studies have performed: While current bladder cancer treatments have limitations, this approach of using a peptide for intravenous drug delivery to the urinary system is a novel strategy for this condition.
Where this research is happening
NEW YORK, UNITED STATES
- WEILL MEDICAL COLL OF CORNELL UNIV — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LAW, BENEDICT SHEK HANG — WEILL MEDICAL COLL OF CORNELL UNIV
- Study coordinator: LAW, BENEDICT SHEK HANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.